TY  - JOUR
AU  - Gillessen, Silke
AU  - Bossi, Alberto
AU  - Davis, Ian D
AU  - de Bono, Johann
AU  - Fizazi, Karim
AU  - James, Nicholas D
AU  - Mottet, Nicolas
AU  - Shore, Neal
AU  - Small, Eric
AU  - Smith, Matthew
AU  - Sweeney, Christopher J
AU  - Tombal, Bertrand
AU  - Antonarakis, Emmanuel S
AU  - Aparicio, Ana M
AU  - Armstrong, Andrew J
AU  - Attard, Gerhardt
AU  - Beer, Tomasz M
AU  - Beltran, Himisha
AU  - Bjartell, Anders
AU  - Blanchard, Pierre
AU  - Briganti, Alberto
AU  - Bristow, Rob G
AU  - Bulbul, Muhammad
AU  - Caffo, Orazio
AU  - Castellano, Daniel
AU  - Castro, Elena
AU  - Cheng, Heather H
AU  - Chi, Kim N
AU  - Chowdhury, Simon
AU  - Clarke, Caroline S
AU  - Clarke, Noel
AU  - Daugaard, Gedske
AU  - De Santis, Maria
AU  - Duran, Ignacio
AU  - Eeles, Ross
AU  - Efstathiou, Eleni
AU  - Efstathiou, Jason
AU  - Ekeke, Onyeanunam Ngozi
AU  - Evans, Christopher P
AU  - Fanti, Stefano
AU  - Feng, Felix Y
AU  - Fonteyne, Valerie
AU  - Fossati, Nicola
AU  - Frydenberg, Mark
AU  - George, Dan
AU  - Gleave, Martin
AU  - Gravis, Gwenaelle
AU  - Halabi, Susan
AU  - Heinrich, Daniel
AU  - Herrmann, Ken
AU  - Higano, Celestia
AU  - Hofman, Michael S
AU  - Horvath, Lisa G
AU  - Hussain, Maha
AU  - Jereczek-Fossa, Barbara A
AU  - Jones, Rob
AU  - Kanesvaran, Ravindran
AU  - Kellokumpu-Lehtinen, Pirkko-Liisa
AU  - Khauli, Raja B
AU  - Klotz, Laurence
AU  - Kramer, Gero
AU  - Leibowitz, Raja
AU  - Logothetis, Christopher
AU  - Mahal, Brandon
AU  - Maluf, Fernando
AU  - Mateo, Joaquin
AU  - Matheson, David
AU  - Mehra, Niven
AU  - Merseburger, Axel
AU  - Morgans, Alicia K
AU  - Morris, Michael J
AU  - Mrabti, Hind
AU  - Mukherji, Deborah
AU  - Murphy, Declan G
AU  - Murthy, Vedang
AU  - Nguyen, Paul L
AU  - Oh, William K
AU  - Ost, Piet
AU  - O'Sullivan, Joe M
AU  - Padhani, Anwar R
AU  - Pezaro, Carmel J
AU  - Poon, Darren M C
AU  - Pritchard, Colin C
AU  - Rabah, Danny M
AU  - Rathkopf, Dana
AU  - Reiter, Robert E
AU  - Rubin, Mark A
AU  - Ryan, Charles J
AU  - Saad, Fred
AU  - Sade, Juan Pablo
AU  - Sartor, Oliver
AU  - Scher, Howard I
AU  - Sharifi, Nima
AU  - Skoneczna, Iwona
AU  - Soule, Howard
AU  - Spratt, Daniel E
AU  - Srinivas, Sandy
AU  - Sternberg, Cora N
AU  - Steuber, Thomas
AU  - Suzuki, Hiroyoshi
AU  - Sydes, Matthew R
AU  - Taplin, Mary-Ellen
AU  - Tilki, Derya
AU  - Türkeri, Levent
AU  - Turco, Fabio
AU  - Uemura, Hiroji
AU  - Uemura, Hirotsugu
AU  - Ürün, Yüksel
AU  - Vale, Claire L
AU  - van Oort, Inge
AU  - Vapiwala, Neha
AU  - Walz, Jochen
AU  - Yamoah, Kosj
AU  - Ye, Dingwei
AU  - Yu, Evan Y
AU  - Zapatero, Almudena
AU  - Zilli, Thomas
AU  - Omlin, Aurelius
TI  - Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
JO  - European journal of cancer
VL  - 185
SN  - 0014-2964
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2023-00672
SP  - 178 - 215
PY  - 2023
AB  - Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to making management decisions in daily clinical practise. The 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) addressed some questions in these areas to supplement guidelines that mostly are based on level 1 evidence.To present the voting results of the APCCC 2022.The experts voted on controversial questions where high-level evidence is mostly lacking: locally advanced prostate cancer; biochemical recurrence after local treatment; metastatic hormone-sensitive, non-metastatic, and metastatic castration-resistant prostate cancer; oligometastatic prostate cancer; and managing side effects of hormonal therapy. A panel of 105 international prostate cancer experts voted on the consensus questions.The panel voted on 198 pre-defined questions, which were developed by 117 voting and non-voting panel members prior to the conference following a modified Delphi process. A total of 116 questions on metastatic and/or castration-resistant prostate cancer are discussed in this manuscript. In 2022, the voting was done by a web-based survey because of COVID-19 restrictions.The voting reflects the expert opinion of these panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results are reported in the supplementary material. We report here on topics in metastatic, hormone-sensitive prostate cancer (mHSPC), non-metastatic, castration-resistant prostate cancer (nmCRPC), metastatic castration-resistant prostate cancer (mCRPC), and oligometastatic and oligoprogressive prostate cancer.These voting results in four specific areas from a panel of experts in advanced prostate cancer can help clinicians and patients navigate controversial areas of management for which high-level evidence is scant or conflicting and can help research funders and policy makers identify information gaps and consider what areas to explore further. However, diagnostic and treatment decisions always have to be individualised based on patient characteristics, including the extent and location of disease, prior treatment(s), co-morbidities, patient preferences, and treatment recommendations and should also incorporate current and emerging clinical evidence and logistic and economic factors. Enrolment in clinical trials is strongly encouraged. Importantly, APCCC 2022 once again identified important gaps where there is non-consensus and that merit evaluation in specifically designed trials.The Advanced Prostate Cancer Consensus Conference (APCCC) provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference aims to share the knowledge of international experts in prostate cancer with healthcare providers worldwide. At each APCCC, an expert panel votes on pre-defined questions that target the most clinically relevant areas of advanced prostate cancer treatment for which there are gaps in knowledge. The results of the voting provide a practical guide to help clinicians discuss therapeutic options with patients and their relatives as part of shared and multidisciplinary decision-making. This report focuses on the advanced setting, covering metastatic hormone-sensitive prostate cancer and both non-metastatic and metastatic castration-resistant prostate cancer.Report of the results of APCCC 2022 for the following topics: mHSPC, nmCRPC, mCRPC, and oligometastatic prostate cancer.At APCCC 2022, clinically important questions in the management of advanced prostate cancer management were identified and discussed, and experts voted on pre-defined consensus questions. The report of the results for metastatic and/or castration-resistant prostate cancer is summarised here.
KW  - Androgen receptor pathway inhibitors (ARPI) (Other)
KW  - Chemotherapy (Other)
KW  - Hormonal treatment (Other)
KW  - Metastatic castration-resistant prostate cancer (mCRPC) and oligometastatic and oligoprogressive prostate cancer (Other)
KW  - Metastatic hormone-sensitive prostate cancer (mHSPC) (Other)
KW  - Next-generation imaging (Other)
KW  - Non metastatic castration-resistant prostate cancer (nmCRPC) (Other)
KW  - PSMA PET-imaging (Other)
KW  - Systemic therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37003085
DO  - DOI:10.1016/j.ejca.2023.02.018
UR  - https://inrepo02.dkfz.de/record/275214
ER  -